To evaluate the feasibility of HSC mobilization and the efficacy and safety of BR120 combined with G-CSF and plerixafor, we conducted a multicenter, open-label, phase II clinical study of BR120 salvage therapy in patients with R/R DLBCL indicated for HDC/AHSCT. The gene discussed is CSF3; the disease is diffuse large B-cell lymphoma.